Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Sileni, Vanna Chiarion ^a   Pigozzo, Jacopo ^a   Ascierto, Paolo Antonio ^b   Grimaldi, Antonio Maria ^b   Maio, Michele ^c   Di Guardo, Lorenza ^d   Marchetti, Paolo ^e,f   De Rosa, Francesco ^g   Nuzzo, Carmen ^h   Testori, Alessandro ⁱ   Cocorocchio, Emilia ⁱ   Bernengo, Maria Grazia ^j   Guida, Michele ^k   Marconcini, Riccardo ^l   Merelli, Barbara ^m   Parmiani, Giorgio ⁿ   Rinaldi, Gaetana ^o   Aglietta, Massimo ^p,q   Grosso, Marco ^r   Queirolo, Paola ^r  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g Immunotherapy Unit Romagna National Cancer Institute   (Italy)

^h REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

ⁱ EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^j Division of Nuclear Medicine 2   (Italy)

^k NATIONAL CANCER CENTRE   (Italy)

^l UNIVERSITY HOSPITAL OF PISA   (Italy)

^m PAPA GIOVANNI XXIII HOSPITAL   (Italy)

ⁿ SAN RAFFAELE HOSPITAL   (Italy)

^o UNIVERSITY OF PALERMO   (Italy)

^p Institute of Cancer Research and Treatment Piedmont Oncology Foundation   (Italy)

^q UNIVERSITY OF TURIN   (Italy)

^r UNIVERSITY OF GENOA   (Italy)

more..

Author keywords

Elderly patients; Expanded access; Ipilimumab; Melanoma; Safety; Treatment outcome

Indexed keywords

IPILIMUMAB;

ADVANCED CANCER; AGED; ARTICLE; COMPASSIONATE USE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; INDUCTION CHEMOTHERAPY; ITALY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; TREATMENT RESPONSE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899543113     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-33-30     Document Type: Article

References (34)

1. Final version of 2009 AJCC melanoma staging and classification. Balch CM, Gershenwald JE, Soong SJ, Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK, J Clin Oncol 2009 27 6199 6206 10.1200/JCO.2009.23.4799 19917835
2. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM, J Clin Oncol 2008 26 527 534 10.1200/JCO.2007.12.7837 18235113 (Pubitemid 351264344)
3. SEER Cancer Statistics Review, 1975-2010. Bethesda M, National Cancer Institute 2012 Available at [http://seer.cancer.gov/statfacts/html/melan.html] (1 July 2013, date last accessed)
4. Cancer statistics, 2010. Jemal A, Siegel R, Xu J, Ward E, CA Cancer J Clin 2010 60 277 300 10.3322/caac.20073 20610543
5. Correlation between prognostic factors and increasing age in melanoma. Chao C, Martin RC, Ross MI, Reintgen DS, Edwards MJ, Noyes RD, Hagendoorn LJ, Stromberg AJ, McMasters KM, Ann Surg Oncol 2004 11 259 264 10.1245/ASO.2004.04. 015 14993020 (Pubitemid 40486765)
6. Age-related lymphatic dysfunction in melanoma patients. Conway WC, Faries MB, Nicholl MB, Terando AM, Glass EC, Sim M, Morton DL, Ann Surg Oncol 2009 16 1548 1552 10.1245/s10434-009-0420-x 19277787
7. Malignant melanoma in the elderly: different regional disease and poorer prognosis. Macdonald JB, Dueck AC, Gray RJ, Wasif N, Swanson DL, Sekulic A, Pockaj BA, J Cancer Educ 2011 2 538 543
8. Melanoma in the elderly patient: relevance of the aging immune system. Hegde UP, Chakraborty N, Kerr P, Grant-Kels JM, Clin Dermatol 2009 27 537 544 10.1016/j.clindermatol.2008.09.012 19880041
9. Metastatic melanoma in the older patient: special considerations. Hegde UP, Grant-Kels JM, Clin Dermatol 2013 31 311 316 10.1016/j.clindermatol.2012.08. 011 23608450
10. New drugs in melanoma: It's a whole new world. Eggermont AMM, Robert C, Eur J Cancer 2011 47 2150 2157 10.1016/j.ejca.2011.06.052 21802280
11. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ, Ann N Y Acad Sci 2013 1291 1 13 10.1111/nyas.12180 23772560
12. Improved survival with ipilimumab in patients with metastatic melanoma. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ, N Engl J Med 2010 363 711 723 10.1056/NEJMoa1003466 20525992
13. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. Robert C, Thomas L, Bondarenko I, O'Day S, JW MD, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD, N Engl J Med 2011 364 2517 2526 10.1056/NEJMoa1104621 21639810
14. Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials. Lebbé C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, O'Day S, Chin KM, Opatt McDowell D, Cykowski L, McHenry B, Wolchok JD, J Clin Oncol 2013 31 suppl bstr 9053
15. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ, Clin Cancer Res 2012 18 2039 2047 10.1158/1078-0432.CCR-11-1823 22271879
16. Ipilimumab improves survival in previously treated advanced melanoma patients with poor prognostic factors: subgroup analysis from a phase III trial. Lebbé C, McDermott DF, Robert C, Lorigan P, Ottensmeier CH, Wolchok J, Garbe C, Messina M, Hoos A, Weber JS, Ann Oncol 2010 21 suppl 8 bstr 13240
17. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Robert C, Ghiringhelli F, Oncologist 2009 14 848 861 19648604
18. Lawrence D, McDermott D, Hamid O, Weber J, Wolchok J, Richards J, Minor D, Pavlick A, Sznol M, Hwu P, Urba W, Amin A, Bennett K, Michener T, Balogh A, Hodi FS, Treatment of Patients (pts) with Stage III or IV Melanoma on an Ipilimumab (Ipi) Expanded Access Program (EAP): Results for 3 mg/kg Cohort Hollywood, USA: Society for Melanoma Research (SMR) Congress 2012
19. Ipilimumab (IPI) Expanded Access Program (EAP) for patients (pts) with Stage III/IV melanoma: safety data by subgroups. Lawrence D, McDermott D, Hamid O, Weber J, Wolchok J, Richards J, Amin A, Bennett K, Balogh A, Hodi FS, Ann Oncol 2012 23 suppl 9 bstr 1129P
20. Ipilimumab in older patients: Spanish melanoma multidisciplinary group (GEM) experience in the expanded access programme. Lopez Martin JA, Gonzalez Cao M, Sereno M, Mayordomo J, Hidalgo M, Campos B, Cumplido D, Zambrana F, Medina J, Berrocal A, Ann Oncol 2012 23 suppl 9 bstr 3233
21. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. Del Vecchio M, Di Guardo L, Ascierto PA, Grimaldi AM, Sileni VC, Pigozzo J, Ferraresi V, Nuzzo C, Rinaldi G, Testori A, Ferrucci PF, Marchetti P, De Galitiis F, Queirolo P, Tornari E, Marconcini R, Calabrò L, Maio M, Eur J Cancer 2014 50 121 127 10.1016/j.ejca.2013.09. 007 24100024
22. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R, De Rosa F, Del Vecchio M, Di Guardo L, Queirolo P, Picasso V, Marchetti P, De Galitiis F, Mandalà M, Guida M, Simeone E, Ascierto PA, Ann Oncol 2013 24 2911 2915 10.1093/annonc/mdt376 24067719
23. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS, Clin Cancer Res 2009 15 7412 7420 10.1158/1078-0432.CCR-09-1624 19934295
24. Italian cohort of the ipilimumab Expanded Access Programme: efficacy, safety and correlation with mutation status in metastatic melanoma patients. Queirolo P, Spagnolo F, Altomonte M, Chiarion-Sileni V, Pigozzo J, Del Vecchio M, Di Guardo L, Ridolfi R, Scoppola A, Francesco Ferrucci P, Ferraresi V, Grazia Bernengo M, Guida M, Marconcini R, Mandalà M, Parmiani G, Rinaldi G, Aglietta M, Simeone E, Antonio Ascierto P, J Clin Oncol 2013 31 suppl bstr 9070
25. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Aapro MS, Köhne C-H, Cohen HJ, Extermann M, Oncologist 2005 10 198 204 10.1634/theoncologist.10-3-198 15793223 (Pubitemid 40463157)
26. Evaluating the safety of anti-CTLA-4 therapy in elderly patients with unresectable melanoma. Chandra S, Madden KM, Kannan R, Pavlick AC, J Clin Oncol 2013 31 suppl bstr 9063
27. Geriatric oncology: challenges for the new century. Balducci L, Eur J Cancer 2000 36 1741 1754 10.1016/S0959-8049(00)00169-6 10974621 (Pubitemid 30639493)
28. Older Patients With Cancer Need Geriatric Assessment. Chustecka Z, MedScape Multispecialty News 2012 Available at [http://www.medscape.com/ viewarticle/773479] (12 February 2014, date last accessed)
29. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF V600E-mutated melanoma. Chapman PB, Hauschild A, Robert C, Larkin JMG, Haanen JBAG, Ribas A, Hogg D, Hamid O, Ascierto PA, Testori A, Lorigan P, Dummer R, Sosman JA, Garbe C, Maio M, Nolop KB, Nelson BJ, Joe AK, Flaherty KT, McArthur GA, J Clin Oncol 2012 30 suppl bstr 8502
30. MDX010-20 Investigators.l. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS, Cancer 2013 119 1675 1682 10.1002/cncr.27969 23400564
31. Management of immune-related adverse events and kinetics of response with ipilimumab. Weber JS, Kahler KC, Hauschild A, J Clin Oncol 2012 30 2691 2697 10.1200/JCO.2012.41.6750 22614989
32. Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma. Larkin JMG, Del Vecchio M, Ascierto PA, Schachter J, Garbe C, Neyns B, Mandala M, Lorigan P, Miller WH, Guminski AD, Berking C, Rutkowski P, Queirolo P, Hauschild A, Arance AM, Brown MP, Mitchell L, Veronese ML, Blank CU, J Clin Oncol 2013 31 suppl bstr 9046
33. Age-associated changes in immune and inflammatory responses: impact of vitamin E intervention. Wu D, Meydani SN, J Leuk Biol 2008 84 900 914 10.1189/jlb.0108023
34. CD40, CD45 CTLA-4 levels are elevated in healthy older adults. Yalcin AD, Gorczynski RM, Kahraman MS, Demirel MU, Terzioglu E, Clin Lab 2012 58 449 456 22783574